drugset / Trial / NCT00757237
Aztreonam for Inhalation Solution vs Tobramycin Inhalation Solution in Patients With Cystic Fibrosis & Pseudomonas Aeruginosa
Phase 3
Completed
274 enrolled
Gilead Sciences
Chiltern International Inc. · collabClinPhone, Inc. · collabCovance · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study was to assess the comparative safety and effectiveness of aztreonam for inhalation solution versus tobramycin inhalation solution in adult and pediatric patients with cystic fibrosis (CF) and pulmonary Pseudomonas aeruginosa (PA) infection.
Timeline
- Start
- 2008-08
- Primary completion
- 2010-05
- Completion
- 2010-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aztreonam | Small molecule | 75 mg | Inhaled |
| Comparator | Tobramycin | Small molecule | 300 mg | Inhaled |